Literature DB >> 2937293

Adverse effects profile of sulfhydryl compounds in man.

I A Jaffe.   

Abstract

Many of the adverse reactions produced by penicillamine and other compounds with an active sulfhydryl group form a distinctive pattern when viewed as a class. Alterations in taste perception, mucocutaneous lesions, proteinuria due to immune-complex membranous glomerulopathy, and pemphigus are adverse reactions that have been encountered with all of the compounds discussed herein. Hematologic reactions such as neutropenia and thrombocytopenia occur rarely and with variable frequency. The angiotension converting enzyme inhibitor captopril has an active sulfhydryl group. When it was first given in high doses to patients with severe hypertension, adverse effects similar in pattern to those just outlined were reported. With reduced doses and more careful patient selection, the more serious reactions are no longer found, but disturbances of taste perception, rash, and oral mucosal ulcers are still encountered.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2937293     DOI: 10.1016/0002-9343(86)90722-9

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  25 in total

1.  Severe cholestatic hepatitis induced by pyritinol.

Authors:  Vasco Maria; Adriana Albuquerque; Ana Loureiro; Ana Sousa; Rui Victorino
Journal:  BMJ       Date:  2004-03-06

Review 2.  Cystinuria: mechanisms and management.

Authors:  Donna J Claes; Elizabeth Jackson
Journal:  Pediatr Nephrol       Date:  2012-01-27       Impact factor: 3.714

3.  Pharmacokinetics of intravenous 2-mercaptopropionylglycine in man.

Authors:  S M Carlsson; T Denneberg; B M Emanuelsson; B Kågedal; S Lindgren
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Dipicolinic Acid Derivatives as Inhibitors of New Delhi Metallo-β-lactamase-1.

Authors:  Allie Y Chen; Pei W Thomas; Alesha C Stewart; Alexander Bergstrom; Zishuo Cheng; Callie Miller; Christopher R Bethel; Steven H Marshall; Cy V Credille; Christopher L Riley; Richard C Page; Robert A Bonomo; Michael W Crowder; David L Tierney; Walter Fast; Seth M Cohen
Journal:  J Med Chem       Date:  2017-08-30       Impact factor: 7.446

5.  Protective effects of tiopronin on oxidatively challenged human lung carcinoma cells (A549).

Authors:  Justin Beltz; Anna Chernatynskaya; Annalise Pfaff; Nuran Ercal
Journal:  Free Radic Res       Date:  2020-05-22

6.  δ-Thiolactones as prodrugs of thiol-based glutamate carboxypeptidase II (GCPII) inhibitors.

Authors:  Dana V Ferraris; Pavel Majer; Chiyou Ni; C Ethan Slusher; Rana Rais; Ying Wu; Krystyna M Wozniak; Jesse Alt; Camilo Rojas; Barbara S Slusher; Takashi Tsukamoto
Journal:  J Med Chem       Date:  2013-12-27       Impact factor: 7.446

7.  Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging.

Authors:  Vincenzo Solfrizzi; Emanuele Scafato; Vincenza Frisardi; Davide Seripa; Giancarlo Logroscino; Patrick G Kehoe; Bruno P Imbimbo; Marzia Baldereschi; Gaetano Crepaldi; Antonio Di Carlo; Lucia Galluzzo; Claudia Gandin; Domenico Inzitari; Stefania Maggi; Alberto Pilotto; Francesco Panza
Journal:  Age (Dordr)       Date:  2011-12-28

Review 8.  Safety profiles of the angiotensin-converting enzyme inhibitors.

Authors:  N J Warner; J E Rush
Journal:  Drugs       Date:  1988       Impact factor: 9.546

9.  Pharmacokinetics of oral tiopronin.

Authors:  M S Carlsson; T Denneberg; B M Emanuelsson; B Kågedal; S Lindgren
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 10.  Angiotensin converting enzyme inhibitors: comparative structure, pharmacokinetics, and pharmacodynamics.

Authors:  G S Thind
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.